

VI

Characteristics of interstitial fibrosis and inflammatory cell infiltration in right ventricles of systemic sclerosis-associated pulmonary arterial hypertension

Maria J. Overbeek^{*}, Koen T.B Mouchaers^{*}, Hans W.M. Niessen^{†,‡}; Awal M. Hadi[‡]; Koba Kupreishvili[‡]; Anco Boonstra^{*}; Alexandre E. Voskuyl[‡]; Jeroen A.M. Belien[‡]; Egbert F. Smit[‡]; Ben C. Dijkmans[‡]; Anton Vonk-Noordegraaf[‡]; Katrien Grünberg[‡]

Departments of ^{*}Pulmonary Diseases, [†]Pathology, [‡]Cardiac Surgery, [‡]Rheumatology; VU University medical center, The Netherlands.

Submitted for publication

R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39

Abstract

Aims: Systemic sclerosis-associated pulmonary arterial hypertension (SScPAH) has a disturbed function of the right ventricle (RV) when compared to idiopathic PAH (IPAH). Systemic sclerosis may also affect the heart. We hypothesize that RV differences may occur at the level of interstitial inflammation and –fibrosis and compared inflammatory cell infiltrate and fibrosis between the RV of SScPAH, IPAH and controls.

Methods and results: Paraffin-embedded tissue samples of RV and left ventricle (LV) from SScPAH (n=5) and IPAH (n=9) patients and controls (n=4) were picrosirius-red stained for detection of interstitial fibrosis, which was quantified semi-automatically. Neutrophilic granulocytes (MPO), macrophages (CD68), and lymphocytes (CD45) were immunohistochemically stained. Only interstitial cells were counted. Presence of epi- or endocardial inflammation, and of perivascular- or intimal fibrosis of coronary arteries was assessed semi-quantitatively. RV’s of SScPAH showed significantly more inflammatory cells than of IPAH (cells/mm², mean±sd MPO 11±3 vs. 6±1; CD68 11±3 vs. 6±1; CD45 11±1 vs. 5±1, p<0.05) and than of controls. SScPAH RV interstitial fibrosis was similar in SScPAH and IPAH (4±1 vs. 5±1%, p=0.9), and did not differ from controls (5±1%, p=0.8). In 4 SScPAH and 5 IPAH RV’s foci of replacement fibrosis were found. No differences were found on epi- or endocardial inflammation or on perivascular- or intimal fibrosis of coronary arteries.

Conclusion: SScPAH RV’s display denser inflammatory infiltrates than IPAH, while they do not differ with respect to interstitial fibrosis. Whether increased inflammatory status is a contributor to altered RV function in SScPAH warrants further research.

R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39

Methods

Patient characteristics

The cases examined in this study were retrieved from the departments of pulmonary diseases of the VU University Medical Center, Amsterdam, the Netherlands. The study was approved by the Institutional Review Board on Research Involving Human Subjects of the VU University Medical Center.

Patients who had been treated for PAH between 1998 and 2007, of whom cardiac tissue obtained at autopsy was available, were deemed eligible for the study. The diagnosis of SScPAH and IPAH was verified by reviewing the medical records including lung function data at baseline as well as HRCT studies. Patients with restrictive disease, as indicated by total lung capacity as percentage of predicted (TLC%) < 70%, vital capacity (VC%) < 70% and/or severe fibrosis on HRCT scan, were classified as pulmonary hypertension due to restrictive disease and therefore excluded from this study. SSc classification, SSc disease duration, and antibody profile were recorded[12,13]. Of the SScPAH group, 3 patients had died of RV failure, one had died of hypovolumic shock due to iatrogenic bleeding and one died post-operatively after lung transplantation (table 1). Eight IPAH patients had died of RV failure and one of haemorrhagia from the arteria pulmonalis.

The hearts from four patients who had acutely died from traumatic, non-cardiopulmonary, non-cerebral causes and who did not have a cardiopulmonary medical history, served as controls.

Tissue preparation and immunohistochemistry

Inflammation

Serial adjacent sections of myocardial tissue (4 μ m thick) were deparaffinised for 10 minutes in xylene at room temperature and dehydrated through ascending concentrations of ethanol. Endogenous peroxidase activity was blocked by incubation in 0.3% (v/v) H₂O₂ in methanol for 30 minutes. Tissue sections were subjected to antigen retrieval by boiling in 10 mM sodium citrate buffer, pH 6.0 for 10 minutes in a microwave oven. All antibodies and normal serum were diluted in PBS containing 1% (w/v) bovine serum albumin (BSA). Tissue sections were pre-incubated for 10 minutes with normal rabbit and normal swine serum (1:50), followed by incubation for 1 hr with either polyclonal rabbit anti-human myeloperoxidase (MPO) (Dako, A0398, Denmark, 1:50 dilution), or mouse monoclonal antibody CD68 (KP1) (Dako, M0814, Denmark, 1:400 dilution) and mouse monoclonal anti-human CD45 (Dako, M0701, Denmark, 1:50 dilution) antibodies. After washing in PBS, tissue slides were incubated for 30 minutes with a biotin-conjugated secondary antibody rabbit anti-

R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39

Fibrosis

Picrosirius-red stained sections of paraffin-embedded cardiac biopsies were scanned in total with Mirax scan system (Zeiss, AG Germany). Areas were randomly selected from the digitised slides at a 20X magnification, covering at least 15% of the total area. Care was taken not to include vessels into the selected areas, to ensure only interstitial myocardial fibrosis was quantified (Figure 1). Interstitial myocardial fibrosis was assessed in the RV and LV, using a fully automated analysis according to Mouchaers *et al.*[17]

In addition, the entire sections were, semiquantitatively, investigated for epicardial - and endocardial fibrosis and scored on a 4-point scale ranging from 0 (absent) to 3 (extensive). Likewise, EvG stained sections were used to score the presence of replacement fibrosis, as defined by fibrotic areas within the myocardium coincident with a loss of cardiomyocytes as well as for perivascular -and intima fibrosis of coronary arteries/arterioles.

Statistical Analysis

For the quantification of interstitial fibrosis and interstitial inflammatory cells, 5 samples of myocardial tissue from the RV and 4 from the LV of SScPAH patients were analysed; 9 samples were available of both the RV and LV from IPAH patients and 4 samples from controls. Mann-Whitney *U* was used to determine differences between means. All histochemical data are presented in graphs as median (range) and patient characteristics in tables as mean+/-SEM. Fisher's exact test was used for comparison of infiltration of inflammatory cells of the endo-/epicardium between groups. $P < 0.05$ was considered statistically significant.

Results

Patient characteristics and haemodynamics

Patient characteristics are listed in Tables 1 and 2. SScPAH and IPAH groups did not differ with respect to mean age. Mean survival of the SScPAH patients was significantly shorter compared to IPAH patients. Haemodynamic parameters at diagnosis were not different between the groups. However, SScPAH patients tended to have a lower mPpa as compared with the IPAH patients. TLCO in the SScPAH group was significantly lower as compared with the IPAH group. Two patients in the SScPAH group and 4 in the IPAH group had been treated with aldosteron antagonists or ACE-inhibitors. None of the patients had systemic hypertension.

Table 1. General patient characteristics

	SScPAH N=5	IPAH N=9	Control N=4
Age, yrs	47 ± 4	47 ± 4	31 ± 4
Male/Female (n)	1/4	2/7	4/0
Survival	1.1 ± 0.5	3.7 ± 0.9	-
mPpa, mmHg	46 ± 7	62 ± 4	
PCWP, mmHg	6 ± 2	5 ± 2	
PVR, dynes·s·cm ⁻⁵	1221 ± 691	1157 ± 144	
CI, l/min·m ²	2.3 ± 0.9	2.3 ± 0.5	
Systolic blood pressure	105 ± 2	118 ± 8	
Diastolic blood pressure	69 ± 6	73 ± 5	
TLC, %	89 ± 5	92 ± 5	
TLCO, %	42 ± 6	64 ± 6	
Therapy at time of death			
Prostacycline (n)	4	7	
ERA (n)	1	2	
PDE-5 inhibitor (n)	1	0	
ABS (n)	0	1	

Values expressed as mean ± SE or otherwise as stated. Abbreviations: ABS: atrial balloon septostomy; CI= cardiac index; TLCO % = percentage of predicted of the transfer factor of the lung for carbon monoxide; ERA: endothelin receptor antagonist; mPpa= mean pulmonary artery pressure; PCWP = pulmonary capillary wedge pressure; PDE-5: phosphodiesterase 5; PVR: pulmonary vascular resistance; IPAH= idiopathic pulmonary arterial hypertension; SScPAH = systemic sclerosis-associated pulmonary arterial hypertension; TLC % = percentage of predicted total lung capacity.

Table 2. Characteristics of SScPAH patients

	Antibody-profile	Cause of death	SSc disease duration (yrs) [†]	Survival after PAH diagnosis (yrs)	Medication at time of death
1	LcSSc* Anti-centromere	RV failure	4	0,5	prostacyclin
2	LcSSc Anti-centromere	RV failure	12	0,75	prostacyclin
3	LcSSc Anti-centromere	RV failure	1	0,08	prostacyclin
4	LcSSc Anti-centromere	Iatrogenic bleeding	1	3	ERA, PDE-5 inhibitor
5	LcSSc ANA	Post- LTX	13	0,42	prostacyclin

Abbreviations: ANA = anti-nucleolar antibody; ERA: endothelin receptor antagonist; LcSSc=Limited cutaneous SSc; LTX = lung transplantation; PDE-5: phosphodiesterase 5; RV = right ventricle; SScPAH = Systemic sclerosis-associated pulmonary arterial hypertension.

[†]According to ¹³. *Since first non-Raynaud symptom, at time of diagnosis of PAH.

R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39

Inflammation

The RV's of SScPAH showed significantly more interstitial MPO- and CD45 positive cells when compared to IPAH. The numbers of MPO-, CD68- and CD45 positive cells/area were also increased when the SScPAH RV's were compared to normal controls (fig 1A, B, C, and examples of immunohistochemical stainings are shown in Figure 2). In the RV of IPAH *vs.* normal controls, no significant differences were observed. In the LV's of SScPAH and IPAH, there were no significant differences in the number of inflammatory cells either. In SScPAH LV's, significantly more CD45 positive cells were observed as compared to normal controls, but no such differences were found for MPO nor for CD68. IPAH LV's demonstrated significantly more CD68 and CD45 as compared with normal controls.

Infiltration of the endocardium and epicardium was not different between the SScPAH and IPAH, nor between RV or LV, for neither cell type (not shown). In all ventricles, a mild perivascular infiltration was observed, but no transmural infiltration of the vessel wall suggestive of vasculitis.

Fibrosis

Representative samples of picrosirius-red stained sections, used for quantification of interstitial fibrosis, are depicted in Figure 3. Interstitial fibrosis in the RV was not different between the SScPAH and IPAH groups (Figure 4). LV interstitial fibrosis did not differ between the three different groups either. Focal epi- and endocardial fibrosis was seen in all subjects.

On EvG-stained sections we analysed putative foci of replacement fibrosis. This was observed in 4 out of 5 RV's from SScPAH patients and in 5 out of 8 RV's from IPAH patients. The LV demonstrated replacement fibrosis in 2 out of 4 SScPAH patients and 5 out of 8 IPAH patients. In most cases this fibrosis was patchy with foci mostly localised subendocardially (Figure 5A). In few cases, a pattern of strands of collagenous fibrous tissue surrounding microvasculature was observed, radiating from the epicardial coronary arteries to the subendocardial myocardium, ending in microscopic fibrotic foci (Figure 5B). In some cases, small infarcts (observed at gross pathology) were observed (1 SScPAH RV, 2 SScPAH LVs and 2 IPAH RVs) (Figure 5C). This was not observed in hearts of control subjects. Finally, we investigated the occurrence of intimal fibrosis in intramyocardial coronary arteries and arterioles. This was observed in SScPAH in 1 RV and 3 LVs and in IPAH in 1 RV. Perivascular fibrosis and adventitial remodeling was equally observed in both SScPAH and IPAH right and left ventricles (Figure 5D). This was not different from controls.

R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39




Figure 2
Representative sections of myocardial tissue stained with antibodies against **A)** neutrophilic granulocytes (MPO positive), **B)** macrophages (CD68 positive) or **C)** lymphocytes (CD45 positive). Arrows indicate positive cells.




Figure 3
Representative samples of picosirius-red stained myocardial sections of the RV of SScPAH and iPAH patients, used for quantification of interstitial fibrosis. Arrows indicate the red-coloured strains of fibrosis.




Figure 4

Quantification of Picosirius-red staining in the RV of SScPAH, IPAH and control subjects in **A)** the RV and **B)** the LV.




Figure 5

Representative samples of Elastic von Gieson (EvG) stained myocardial sections of the RV of SScPAH patients, used for studying fibrosis in detail. **A)** Some RV's of SScPAH patients revealed a pattern patchy replacement fibrosis, mostly localised subendocardially. This was also seen in some hearts of IPAH patients, but not observed in control. **B)** In few cases, a pattern of strands of collagenous fibrous tissue surrounding microvasculature was observed, radiating from the epicardial coronary arteries to the subendocardial myocardium. **C)** In some cases small infarcts in both SScPAH and IPAH hearts were observed. **D)** An increase in perivascular fibrosis in some SScPAH hearts and in 1 IPAH heart was observed. All of these observations were not made in control hearts.

R1
R2
R3
R4
R5
R6
R7
R8
R9
R1
R1
R1
R1
R1
R1
R1
R1
R1
R2
R2
R2
R2
R2
R2
R2
R2
R2
R2
R3
R3
R3
R3
R3
R3
R3
R3
R3
R3
R3

Discussion

In this study, for the first time, histopathologic features of fibrosis and inflammatory status are described in the interstitial myocardium of the RV in a well-documented SScPAH group. As RV's of SScPAH patients have worse function than IPAH RV's, comparison took place with IPAH RV's. We observed significantly more extravascular inflammatory cells in the myocardial interstitium of the RV of SScPAH as compared with the RV of IPAH and as compared with normal controls. No significant difference in this respect was found between IPAH RV's and control RV's, nor between the LV's of both PAH disease groups. Interstitial myocardial fibrosis in the RV did not significantly differ between SScPAH and IPAH, nor between the PAH disease groups and normal controls. No differences were found with respect to interstitial fibrosis for the LV either. Although PAH patients had more replacement-, perivascular-, and subendocardial fibrosis when compared to controls, no differences were found between SScPAH and IPAH patients.

The presence of inflammatory cells in (interstitial) myocardial tissue in SScPAH has not been described previously. Two SSc cases with clinical LV failure, but without signs of increased RV afterload, have been described, demonstrating an increase in T-cells and CD68 positive cells in endomyocardial biopsies of the RV[18]. In IPAH, interstitial inflammatory cell infiltration in the RV did not differ significantly from normal controls in a previous report [16], which is in agreement with the present findings.

Fibrosis in hearts of SSc patients has been shown in autopsy studies, and tended to be patchy and distributed throughout all levels of the myocardium of the RV and LV[19-23]. In endomyocardial biopsies of RV's of SSc patients, Fernandes *et al.* [24] found increased collagen deposition as compared with normal controls. None of the above described studies included patients with confirmed pulmonary (arterial) hypertension. A recent study on cardiac MRI features in 52 SSc patients described delayed contrast enhancement, indicating the presence of myocardial fibrosis, in 1 of 8 SScPAH patients[25]. In IPAH, fibrosis in endomyocardial biopsies of the RV has been reported to be "mildly" increased, however, quantification nor specification concerning location was reported[26].

The study is limited by the small sample size. Despite this, the examined SScPAH RV histology is unique and has not been subject of study previously, set apart from the SSc group as a whole. Special care was taken to include only cases in which both the diagnosis of SSc and PAH was unequivocal, so as to reduce inhomogeneity, and thereby optimize statistical power. We therefore think that the exploratory data presented here provide relevant insight, warranting further study. An inherent

limitation of this study is the use of archival autopsy material, which is shared by previous studies on this topic. As practically all patients died of PAH-related causes, the pathology in this series represents end-stage disease. Consequently, its features might differ from earlier and subclinical phases of the same disease. Sampling and processing of the RV and LV is often not done in a standardized way over the years. However, this was unlikely to be of influence on the immunohistochemical stainings, as an internal positive control was present in all slides, and staining intensity was irrelevant. The observation that even in end-stage disease significant differences were found in inflammatory cells suggests different pathogenic pathways.

How do we interpret the elevated numbers of interstitial inflammatory cells in the RV of SScPAH hearts compared to IPAH? Mechanical stress due to RV pressure overload could be responsible for this finding as such a difference was not found when the LV's of both disease groups were compared. Indeed, increased mechanical stress may induce cytokine expression (e.g. monocyte chemoattractant protein-1 (MCP1) and interleukin (IL)-8) in several cell types such as endothelial cells and cardiomyocytes [27,28] through production of reactive oxygen species (ROS) with secondary activation of NF- κ B[29].

Increased susceptibility to ischemia, which is known to induce inflammatory cytokines, might also explain increased inflammatory cell infiltration in SScPAH, as structural and functional abnormalities of the small coronary arteries are known features of SSc[19,30-33]. However, in the present study we did not find differences in the presence of arteriolar intimal fibrosis between SScPAH and IPAH RV's.

It is unclear whether the inflammatory cells are innocent bystanders or whether they play an active role in altered RV function in SScPAH. Most links between inflammation and a reduced contractility in chronic heart diseases have been forged on the basis of cytokines and chemokines [27,28,34-37] but there are limited data on the effect of cardiac tissue injury by neutrophils. In addition, it is known that macrophages can directly impair contractility of individual cardiomyocytes[38-42].

A significantly higher CD45-positive cell infiltration was found in the LV's of both SScPAH and IPAH as compared with controls, which is difficult to explain; systemic inflammatory factors might not clarify this finding, as there was no increase of neutrophilic granulocytes or macrophages. Increased CD45 infiltration of the myocardium is seen in viral myocarditis [43], however, in none of the patients other signs of myocarditis, such as necrosis or degradation of myocytes along with lymphocytic infiltrates, was seen.

We found no quantitative differences of interstitial fibrosis between SScPAH and IPAH. This, however, does not exclude that the composition or structure of the extracellular matrix components is different in SScPAH, which may result in different

R1
R2
R3
R4
R5
R6
R7
R8
R9
R1
R1
R1
R1
R1
R1
R1
R1
R1
R2
R2
R2
R2
R2
R2
R2
R2
R2
R2
R2
R2
R3
R3
R3
R3
R3
R3
R3
R3
R3
R3
R3

R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39

effects on ventricular function[41,44,45]. In agreement with previous reports, we did observe patchy and moderate replacement fibrosis in several hearts of SScPAH patients, both in the RV and LV.[19,21-23] Replacement fibrosis is the end-result of either inflammation mediated and / or ischemia-mediated damage[46]. It is not clear in this study which mechanism predominates in SScPAH. As replacement fibrosis was also observed in IPAH patients, but not in control hearts, the focal fibrosis may ultimately be the result of increased RV pressure overload in pulmonary hypertension, regardless of its cause.

In conclusion, the present study shows an increased number of inflammatory cells in the RV myocardial interstitium in SScPAH as compared with IPAH. No differences in (interstitial) fibrosis between the groups were found. Further research is warranted to evaluate the significance of these findings for the RV function in SScPAH patients.

Reference List

1. Gabrielli A, Avvedimento EV, Krieg T: **Scleroderma**. *N Engl J Med* 2009, **360**: 1989-2003.
2. Steen VD, Medsger TA: **Changes in causes of death in systemic sclerosis, 1972-2002**. *Ann Rheum Dis* 2007, **66**: 940-944.
3. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapai F *et al.*: **Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era**. *Am J Respir Crit Care Med* 2009, **179**: 151-157.
4. Hachulla E, Carpentier P, Gressin V, Diot E, Allanore Y, Sibilia J *et al.*: **Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study**. *Rheumatology (Oxford)* 2009.
5. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE: **Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis**. *Chest* 2003, **123**: 344-350.
6. Dorfmueller P, Humbert M, Perros F, Sanchez O, Simonneau G, Muller KM *et al.*: **Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases**. *Hum Pathol* 2007, **38**: 893-902.
7. Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC: **Age and risk of pulmonary arterial hypertension in scleroderma**. *Chest* 2003, **124**: 2098-2104.
8. Fisher MR, Mathai SC, Champion HC, Gargis RE, Houston-Harris T, Hummers L *et al.*: **Clinical differences between idiopathic and scleroderma-related pulmonary hypertension**. *Arthritis Rheum* 2006, **54**: 3043-3050.
9. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE: **Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis**. *Chest* 2003, **123**: 344-350.
10. Overbeek MJ, Lankhaar JW, Westerhof N, Voskuyl AE, Boonstra A, Bronzwaer JG *et al.*: **Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension**. *Eur Respir J* 2008, **31**: 1160-1166.
11. Mathai SC, Bueso M, Hummers LK, Boyce D, Lechtzin N, Le PJ, *et al.*: **Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension**. *Eur Respir J* 2010; **35**: 95-104.
12. **Preliminary criteria for the classification of systemic sclerosis (scleroderma)**. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. *Arthritis Rheum* 1980, **23**: 581-590.
13. LeRoy EC: **Scleroderma (systemic sclerosis): classification, subsets and pathogenesis**. *J Rheumatol* 1988; **15**: 202-5.
14. Junqueira LC, Bignolas G, Brentani RR: **Picosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections**. *Histochem J* 1979, **11**: 447-455.

R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39

15. Puchtler H, Waldrop FS, Valentine LS: **Polarization microscopic studies of connective tissue stained with picro-sirius red FBA.** *Beitr Pathol* 1973, **150**: 174-187.
16. Begieneman MP: **Pulmonary embolism causes endomyocarditis in the human heart.** *Heart* 2008;**94**:450-6.
17. Mouchaers KT: **Automated quantification of fibrosis in myocardium.** *FASEB J* 2008. 1123.27. Abstract.
18. Liangos O: **The possible role of myocardial biopsy in systemic sclerosis.** *Rheumatology* 2000; **39**:674-9.
19. Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM: **Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction.** *Circulation* 1976, **53**: 483-490.
20. Deswal A, Follansbee WP: **Cardiac involvement in scleroderma.** *Rheum Dis Clin North Am* 1996, **22**: 841-860.
21. Follansbee WP, Miller TR, Curtiss EI, Orié JE, Bernstein RL, Kiernan JM *et al.*: **A controlled clinicopathologic study of myocardial fibrosis in systemic sclerosis (scleroderma).** *J Rheumatol* 1990, **17**: 656-662.
22. Leinwand I: **Generalized scleroderma; report with autopsy findings.** *Ann Intern Med* 1951, **34**: 226-238.
23. Sackner MA, Heinz ER, Steinberg AJ: **The heart in scleroderma.** *Am J Cardiol* 1966, **17**: 542-559.
24. Fernandes F, Ramires FJ, Arteaga E, Ianni BM, Bonfa ES, Mady C: **Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study.** *J Card Fail* 2003, **9**: 311-317.
25. Hachulla AL, Launay D, Gaxotte V, de GP, Lamblin N, Devos P, *et al.* : **Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients.** *Ann Rheum Dis* 2009; **68**:1878-84.
26. Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohlmeier TJ, Quaipe RA *et al.*: **Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium.** *J Clin Invest* 1997, **100**: 2315-2324.
27. Okada M, Matsumori A, Ono K, Furukawa Y, Shioi T, Iwasaki A *et al.*: **Cyclic stretch upregulates production of interleukin-8 and monocyte chemoattractant and activating factor/monocyte chemoattractant protein-1 in human endothelial cells.** *Arterioscler Thromb Vasc Biol* 1998, **18**: 894-901.
28. Shioi T, Matsumori A, Kihara Y, Inoko M, Ono K, Iwanaga Y *et al.*: **Increased expression of interleukin-1 beta and monocyte chemoattractant and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload.** *Circ Res* 1997, **81**: 664-671.
29. Li N, Karin M: **Is NF-kappaB the sensor of oxidative stress?** *FASEB J* 1999, **13**: 1137-1143.
30. James TN: **De subitaneis mortibus. VIII. Coronary arteries and conduction system in scleroderma heart disease.** *Circulation* 1974, **50**: 844-856.

31. Kahan A, Devaux JY, Amor B, Menkes CJ, Weber S, Nitenberg A *et al.*: **Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis.** *N Engl J Med* 1986, **314**: 1397-1402.
32. Montisci R, Vacca A, Garau P, Colonna P, Ruscazio M, Passiu G *et al.*: **Detection of early impairment of coronary flow reserve in patients with systemic sclerosis.** *Ann Rheum Dis* 2003, **62**: 890-893.
33. Kahan A, Nitenberg A, Foulst JM, Amor B, Menkes CJ, Devaux JY *et al.*: **Decreased coronary reserve in primary scleroderma myocardial disease.** *Arthritis Rheum* 1985, **28**: 637-646.
34. Aukrust P, Gullestad L, Ueland T, Damas JK, Yndestad A: **Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications.** *Ann Med* 2005, **37**: 74-85.
35. Gullestad L, Aukrust P: **The cytokine network in heart failure: pathogenetic importance and potential therapeutic targets.** *Heart Fail Monit* 2001, **2**: 8-13.
36. Singal PK, Khaper N, Palace V, Kumar D: **The role of oxidative stress in the genesis of heart disease.** *Cardiovasc Res* 1998, **40**: 426-432.
37. Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L, Aukrust P: **Systemic inflammation in heart failure--the whys and wherefores.** *Heart Fail Rev* 2006, **11**: 83-92.
38. Davani EY, Boyd JH, Dorscheid DR, Wang Y, Meredith A, Chau E *et al.*: **Cardiac ICAM-1 mediates leukocyte-dependent decreased ventricular contractility in endotoxemic mice.** *Cardiovasc Res* 2006, **72**: 134-142.
39. Granton JT, Goddard CM, Allard MF, van ES, Walley KR: **Leukocytes and decreased left-ventricular contractility during endotoxemia in rabbits.** *Am J Respir Crit Care Med* 1997, **155**: 1977-1983.
40. Simms MG, Walley KR: **Activated macrophages decrease rat cardiac myocyte contractility: importance of ICAM-1-dependent adhesion.** *Am J Physiol* 1999, **277**: H253-H260.
41. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL: **beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling.** *Circulation* 2000, **101**: 2103-2109.
42. Wei GC, Sirois MG, Qu R, Liu P, Rouleau JL: **Subacute and chronic effects of quinapril on cardiac cytokine expression, remodeling, and function after myocardial infarction in the rat.** *J Cardiovasc Pharmacol* 2002, **39**: 842-850.
43. Chow LH, Ye Y, Linder J, McManus BM: **Phenotypic analysis of infiltrating cells in human myocarditis. An immunohistochemical study in paraffin-embedded tissue.** *Arch Pathol Lab Med* 1989, **113**: 1357-1362.
44. Bogaard HJ, Abe K, Vonk-Noordegraaf A, Voelkel NF: **The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension.** *Chest* 2009, **135**: 794-804.

R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39

45. Brinckmann J, Neess CM, Gaber Y, Sobhi H, Notbohm H, Hunzelmann N *et al.*: **Different pattern of collagen cross-links in two sclerotic skin diseases: lipodermatosclerosis and circumscribed scleroderma.** *J Invest Dermatol* 2001, **117**: 269-273.
46. Kumar V, Abbas AK, Fausto N: **Pathologic basis of disease**, 7 edn. Philadelphia: 2005.